PAXIS: A randomized, double-blind, placebo-controlled dose-finding phase 2 study (Part 1) followed by an open-label period (Part 2) to assess the efficacy and safety of pacritinib in patients with VEXAS syndrome (PAXIS)

Principal Investigator

Dr Onima Chowdhury

Contact us

Email: Latephasehaematology@ouh.nhs.uk

IRAS number

1010876